Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- GARDP, Indian Firm Ink Deal to Expand Access to Shionogi Antibiotic
September 13, 2023
- Eisai Sets Up Digital Biz Unit to Build Dementia Ecosystem
September 13, 2023
- Takeda Shoots for 80% Cut in Paper Materials, Switch to All-EV/HV Fleet by FY2025
September 12, 2023
- Daiichi Sankyo’s HER3 ADC Posts Positive PII Data in 3rd Line NSCLC, US Filing Eyed by March
September 12, 2023
- EA Pharma, China’s TransThera Hook Up on GI Drug Research
September 12, 2023
- GSK Files Myelofibrosis Drug Momelotinib in Japan
September 12, 2023
- China’s Haihe Makes Japan Debut with NDA Filing of Lung Cancer Drug
September 12, 2023
- Sumitomo to Ramp Up Regenerative, Cell Therapy Biz to Counter Latuda Patent Cliff
September 11, 2023
- Otsuka, Shape Link Up on AAV Gene Therapies for Eye Diseases
September 11, 2023
- TA-MUC1-Directed ADC Enters Clinic for Solid Tumors: Daiichi Sankyo
September 11, 2023
- Japan Ethical Drug Sales Up 7.9% in July: Crecon
September 11, 2023
- After Idorsia Deal, Sosei Pivoting to High-Profit Model with In-House Sales System
September 8, 2023
- Astellas Drops IRA Lawsuit after Xtandi Avoids 1st Drug List
September 8, 2023
- Daiichi Sankyo Files XBB.1.5 COVID Jab, Eyes Japan Rollout by Year-End
September 8, 2023
- Maruho Gets Asia Rights to Hyperhidrosis Wipe Drug
September 8, 2023
- Keytuda Filed in Japan in NSCLC Neoadjuvant/Adjuvant Setting: MSD
September 8, 2023
- Brexpiprazole Combo Logs Mixed Results in 2 PTSD Trials: Otsuka/Lundbeck
September 8, 2023
- Noile-Immune Hits Early Milestone for CAR-T Tech Transfer to Chugai
September 7, 2023
- PNH Drug Crovalimab Accepted for FDA Review: Chugai
September 7, 2023
- Daiichi Sankyo’s Omicron-Tailored Booster Hits Main Goal: Japan PIII
September 7, 2023
ページ
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…